Important Notes
This annual report summary is derived from the full annual report. To fully understand the company's operating results, financial status, and future development plans, investors should carefully read the full annual report published in designated media by the CSRC. All directors attended the board meeting to review this report.
Non-standard audit opinion: □ Applicable ☑ Not applicable
Profit distribution plan or capital reserve transfer plan reviewed by the board during the reporting period: ☑ Applicable □ Not applicable
Is there a capital reserve transfer plan? □ Yes ☑ No
The proposed cash dividend for this period is calculated together with the special dividend implemented in 2025. Based on the total share capital of 1,784,262,603 shares at the end of 2025, the total cash dividend for the year accounts for 90.09% of the net profit attributable to shareholders of the listed company, totaling 4,642,651,293.01 yuan (including tax). The special dividend distribution was completed on September 2025, with a cash distribution of 10.19 yuan (including tax) for every 10 shares, totaling 1,818,163,592.46 yuan (including tax). The profit distribution plan for 2025 is to distribute a cash dividend of 15.83 yuan (including tax) for every 10 shares based on the total share capital of 1,784,262,603 shares at the end of 2025, with no bonus shares issued and no capital reserve transfer.
Board resolution on preferred stock profit distribution plan: □ Applicable ☑ Not applicable
Company Overview
-
Company Profile
Stock abbreviation: Yunnan Baiyao
Stock code: 000538
Stock exchange: Shenzhen Stock Exchange
Previous stock abbreviation (if any): None
Contact person and contact information:
Board Secretary: Qian Yinghui
Securities Affairs Representative: Li Mengjue
Office address: No. 3686, Yunnan Baiyao Street, Chenggong District, Kunming, Yunnan Province
Fax: 0871-66203531
Phone: 0871-66226106
Email: 000538dm@ynby.cn -
Main Business or Product Overview
The company focuses on four core business groups: pharmaceuticals, health products, traditional Chinese medicine resources, and Yunnan Provincial Pharmaceutical Company. The pharmaceutical group aims to be the "first brand" in comprehensive management of trauma and pain, focusing on the Yunnan Baiyao series products, while also developing traditional Chinese medicine brands in various fields. The health products group targets high-quality health lifestyle products, emphasizing oral health and exploring new consumer scenarios. The traditional Chinese medicine resources group aims to ensure high-quality, efficient, and low-cost supply of medicinal materials. The Yunnan Provincial Pharmaceutical Company focuses on maintaining its leading market share in the pharmaceutical distribution industry in Yunnan Province. -
Key Accounting Data and Financial Indicators
(1) Key accounting data and financial indicators for the past three years
Is retrospective adjustment or restatement of previous years' accounting data required? □ Yes ☑ No
Unit: Yuan